Sagent Pharmaceuticals (SGNT) announces the approval and launch of its Zoledronic Acid Injection, the generic form of Zometa, in a plastic vial. The U.S. market for Zoledronic Acid Injection is approximately $606M. Additionally, the company says its amended its manufacturing and supply agreement with Actavis (ACT) which provides for an enhanced profit split in favor of SGNT, plus a revised line-up of products and a one-time termination fee of $5 million payable to Sagent.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Jan 13, 2015)
at Benzinga.com (Jan 9, 2015)
Top 4 NASDAQ Stocks In The Drugs Generic Industry With The Highest EPS Growth Forecast For Next 5 Yearsat Benzinga.com (Dec 29, 2014)
at Benzinga.com (Dec 18, 2014)
at CNBC.com (May 5, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs